Reata Friedreich's Ataxia Drug Shows Late-Stage MOXIe
Reacquiring rights to omaveloxolone from AbbVie looks great business
Analysts have been surprised by positive pivotal data for omaveloxolone, one of Reata's Nrf2 activators – along with bardoxolone – which the company is buying back from AbbVie for $330m.
